47 years old woman with palpable left breast mass, 4 cm. Left breast lumpectomy. Mass forming pseudoangiomatous stromal hyperplasia (PASH). #breastpath MSK Department of Pathology & Laboratory Medicine Edi Brogi @fcschmitt Stuart Schnitt Laura Collins Jenny Pincus, MD Liza Quintana, MD Samson W. Fine, MD Hannah Wen

Pathogenesis of Triple-Negative Breast Cancer #TNBC Triple Negative Breast Cancer Foundation Breast Cancer Research Updates The Breast Cancer Research Foundation Sloan-Kettering pubmed.ncbi.nlm.nih.gov/35073169/

"Do you think it's possible to predict, based on the genomic profile of an individual tumor, which organs it might metastasize to?" Data from 25,000 patients published in Cell Press is helping MSK scientists answer this & many other important Qs. bit.ly/3uoSXqC

FDA approved olaparib (Lynparza, AstraZeneca) for adjuvant treatment of patients with deleterious or suspected deleterious germline BRCA-mutated HER2 negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. fda.gov/drugs/resource…

A huge Thank You to our outstanding speakers Dr. Laura Collins, Dr. Patricia Ganz, Dr. Torsten Nielsen ISBP companion meeting USCAP. Laura Collins Liza Quintana, MD Edi Brogi @fcschmitt Gelareh Farshid Hannah Wen Stuart Schnitt

A new ASCO guideline update: Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-risk, Early-stage Triple Negative #BreastCancer ➡️ fal.cn/3nLKz #JCO #bcsm

Mastectomy post neoadjuvant therapy. Extensive LVI mimicking DCIS. IHC for D2-40 (left) and p63 (right). #breastpath Edi Brogi @fcschmitt Laura Collins Stuart Schnitt Liza Quintana, MD Anne Grabenstetter Melissa Krystel-Whittemore, MD MSK Department of Pathology & Laboratory Medicine Gelareh Farshid Hannah Wen

60 yo man with 2 cm breast mass. One of the BEST examples ever! Can you make diagnosis from one pic, or is it #TooCloseToDiagnose? WSI digital slide: kikoxp.com/posts/4600. Answer & video: kikoxp.com/posts/9332. #pathologists #pathology #pathTwitter #BSTpath #breastpath

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer | NEJM nejm.org/doi/full/10.10… @fcschmitt Gelareh Farshid Edi Brogi Dr Kimberly Allison

Accepting someone for who they are means accepting the choices they made that, in turn, made them. Even if you might not understand those choices. Even if you might not have made the same choices. You can still accept them.

Check it out! This new issue of Surgical Clinics on #sarcoma is out! See here a recap of the whole table of contents! The Ever-Evolving Landscape of Sarcomas: A 2022 Update on This Complex Family of Diseases surgonc.theclinics.com/article/S1055-… Chandrajit Raut Timothy M. Pawlik CTOS (1/15)

Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial ascopubs.org/doi/10.1200/JC…

Who dares answer these questions? Deep soft tissue tumor of the foot in a 50+ male. Low power: partly nested to fascicular with transecting fibrous bands. High power, the cells are uniform, ovoid with pale to clear cytoplasm and prominent nucleoli.

Thankyou AProf Cooper for presenting our poster at the The Australasian Division of the IAP showing underrepresentation of women in leadership positions, academia and awards. It is great to stimulate discussions about this Fiona Maclean @CArnold_Coach Xiaoyin "Sara" Jiang, MD (She/Her) Ruta Gupta @SaraEWobker Vikram Deshpande

smh.com.au/politics/feder… It can be done “Progress is not linear. Gender equality does not happen unless we measure it and report on it, and ensure we guard against conscious and unconscious bias. @SaraEWobker Laura J. Tafe, MD Ruta Gupta Fiona Maclean jane dahlstrom Priyanthi Kumarasinghe

Hi all! Feeling great in neuro ICU at #RPAH/Sydney Local Health District. Thanks so much to my friend & colleague Dr Brindha Shivalingam & team for meeting with my wife Dr Katie Nicoll & Professor Georgina Long AO (Bluesky @gvlongphdmd) yesterday & for operating on me today! Thanks to friends & colleagues around world & Melanoma Institute Australia

We're pleased to announce our Impact Factor for Pathology Journal is 4.5, with a ranking of 18/76 among the world’s #pathology journals. Thank you and kudos to our authors, peer reviewers, editorial board and Editor-in-Chief @ProfRScolyerMIA. Source: Clarivate 2023 #JCR2023

We have uncovered a new molecular mechanism responsible for nearly one-third of sporadic schwannomas – recurrent insertion/deletion mutations in 𝑆𝑂𝑋10. doi.org/10.1093/neuonc…

Intubated ICU patients using VR to take a short immersive vacation while getting some physical exercise in. Source: darlan nitz

Great session at the ISBpath in Baltimore